274 related articles for article (PubMed ID: 35442747)
1. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy.
Zou Y; Sun X; Yang Q; Zheng M; Shimoni O; Ruan W; Wang Y; Zhang D; Yin J; Huang X; Tao W; Park JB; Liang XJ; Leong KW; Shi B
Sci Adv; 2022 Apr; 8(16):eabm8011. PubMed ID: 35442747
[TBL] [Abstract][Full Text] [Related]
2. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy.
Ruan W; Jiao M; Xu S; Ismail M; Xie X; An Y; Guo H; Qian R; Shi B; Zheng M
J Control Release; 2022 Nov; 351():739-751. PubMed ID: 36174804
[TBL] [Abstract][Full Text] [Related]
3. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing.
Chen G; Abdeen AA; Wang Y; Shahi PK; Robertson S; Xie R; Suzuki M; Pattnaik BR; Saha K; Gong S
Nat Nanotechnol; 2019 Oct; 14(10):974-980. PubMed ID: 31501532
[TBL] [Abstract][Full Text] [Related]
4. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
[TBL] [Abstract][Full Text] [Related]
5. Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain.
Abbasi S; Uchida S; Toh K; Tockary TA; Dirisala A; Hayashi K; Fukushima S; Kataoka K
J Control Release; 2021 Apr; 332():260-268. PubMed ID: 33647431
[TBL] [Abstract][Full Text] [Related]
6. Autonomous Feedback-Driven Engineered DNAzyme-Coated Trojan Horse-like Nanocapsules for On-Demand CRISPR/Cas9 Delivery.
Tang X; Chen Y; Wang B; Luo D; Wang J; He Y; Feng L; Xu Y; Xie S; Chen M; Chang K
ACS Nano; 2024 May; 18(21):13950-13965. PubMed ID: 38751197
[TBL] [Abstract][Full Text] [Related]
7. Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma.
Liu X; Cao Z; Wang W; Zou C; Wang Y; Pan L; Jia B; Zhang K; Zhang W; Li W; Hao Q; Zhang Y; Zhang W; Xue X; Lin W; Li M; Gu J
ACS Nano; 2023 Sep; 17(17):16432-16447. PubMed ID: 37646615
[TBL] [Abstract][Full Text] [Related]
8. Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins.
Metzger JM; Wang Y; Neuman SS; Snow KJ; Murray SA; Lutz CM; Bondarenko V; Felton J; Gimse K; Xie R; Li D; Zhao Y; Flowers MT; Simmons HA; Roy S; Saha K; Levine JE; Emborg ME; Gong S
Biomaterials; 2023 Feb; 293():121959. PubMed ID: 36527789
[TBL] [Abstract][Full Text] [Related]
9. sgRNA Sequence Motifs Blocking Efficient CRISPR/Cas9-Mediated Gene Editing.
Graf R; Li X; Chu VT; Rajewsky K
Cell Rep; 2019 Jan; 26(5):1098-1103.e3. PubMed ID: 30699341
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-responsive release of Cas9/sgRNA from DNA nanoflower for cytosolic protein delivery and enhanced genome editing.
Shi J; Yang X; Li Y; Wang D; Liu W; Zhang Z; Liu J; Zhang K
Biomaterials; 2020 Oct; 256():120221. PubMed ID: 32738651
[TBL] [Abstract][Full Text] [Related]
11. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
12. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S; Shen J; Li D; Cheng Y
Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
[TBL] [Abstract][Full Text] [Related]
13. [Advances of Cas9/sgRNA delivery system for gene editing].
Hu X; Wang S; Yu L; Zhang X; Chen W
Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3880-3889. PubMed ID: 34841792
[TBL] [Abstract][Full Text] [Related]
14. Single siRNA Nanocapsules for Effective siRNA Brain Delivery and Glioblastoma Treatment.
Zou Y; Sun X; Wang Y; Yan C; Liu Y; Li J; Zhang D; Zheng M; Chung RS; Shi B
Adv Mater; 2020 Jun; 32(24):e2000416. PubMed ID: 32374446
[TBL] [Abstract][Full Text] [Related]
15. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
Bai B; Myklebust JH; Wälchli S
Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
[TBL] [Abstract][Full Text] [Related]
16. Efficient Multi-Allelic Genome Editing of Primary Cell Cultures via CRISPR-Cas9 Ribonucleoprotein Nucleofection.
Hoellerbauer P; Kufeld M; Paddison PJ
Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e126. PubMed ID: 32833346
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two loci.
Chylinski K; Hubmann M; Hanna RE; Yanchus C; Michlits G; Uijttewaal ECH; Doench J; Schramek D; Elling U
Nat Commun; 2019 Nov; 10(1):5454. PubMed ID: 31784531
[TBL] [Abstract][Full Text] [Related]
18. Design of a generic CRISPR-Cas9 approach using the same sgRNA to perform gene editing at distinct loci.
Najah S; Saulnier C; Pernodet JL; Bury-Moné S
BMC Biotechnol; 2019 Mar; 19(1):18. PubMed ID: 30894153
[TBL] [Abstract][Full Text] [Related]
19. Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system.
Matson AW; Hosny N; Swanson ZA; Hering BJ; Burlak C
PLoS One; 2019; 14(12):e0226107. PubMed ID: 31821359
[TBL] [Abstract][Full Text] [Related]
20. An Optimized CRISPR/Cas9 Adenovirus Vector (AdZ-CRISPR) for High-Throughput Cloning of sgRNA, Using Enhanced sgRNA and Cas9 Variants.
Statkute E; Wang ECY; Stanton RJ
Hum Gene Ther; 2022 Sep; 33(17-18):990-1001. PubMed ID: 35196879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
